Literature DB >> 21524747

High plasma cholesteryl ester transfer but not CETP mass predicts incident cardiovascular disease: a nested case-control study.

Paul J W H Kappelle1, Frank Perton, Hans L Hillege, Geesje M Dallinga-Thie, Robin P F Dullaart.   

Abstract

OBJECTIVE: The relationship of cardiovascular disease (CVD) with plasma cholesteryl ester transfer protein (CETP) levels is controversial. We determined whether plasma cholesteryl ester transfer (CET), reflecting CETP-mediated transfer of cholesteryl esters from endogenous HDL towards apolipoprotein B-lipoproteins, predicts incident CVD.
METHODS: A prospective nested case-control study was carried out in 114 men who developed CVD and 105 controls. Participants did not use lipid lowering drugs at baseline. Plasma CET was assayed using an isotope method.
RESULTS: Plasma CET was 19% higher (P=0.030), whereas CETP mass was unaltered (P=0.30) in cases vs. controls. Plasma CET predicted CVD (age-adjusted hazard ratio (HR): 1.20 (95% CI 1.02-1.46, P=0.028), but incident CVD was unrelated to CETP mass (HR: 0.88 (95% CI 0.73-1.07), P=0.20). Plasma CET still predicted CVD after additional adjustment for total cholesterol/HDL cholesterol, triglycerides and non-lipid risk markers (HR: 1.22 (95% CI 1.02-1.46, P=0.031).
CONCLUSION: Plasma CET rather than CETP mass may be a determinant of cardiovascular risk.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21524747     DOI: 10.1016/j.atherosclerosis.2011.03.020

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

Review 1.  HDL-targeted therapies: progress, failures and future.

Authors:  Bronwyn A Kingwell; M John Chapman; Anatol Kontush; Norman E Miller
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

2.  Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.

Authors:  Daniel B Larach; Marina Cuchel; Daniel J Rader
Journal:  Clin Lipidol       Date:  2013-12

3.  Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study.

Authors:  Sander J Robins; Asya Lyass; Robert W Brocia; Joseph M Massaro; Ramachandran S Vasan
Journal:  Atherosclerosis       Date:  2013-02-18       Impact factor: 5.162

Review 4.  CETP Inhibition in CVD Prevention: an Actual Appraisal.

Authors:  Belinda Di Bartolo; Kohei Takata; MyNgan Duong; Stephen J Nicholls
Journal:  Curr Cardiol Rep       Date:  2016-05       Impact factor: 2.931

Review 5.  Low-normal thyroid function and novel cardiometabolic biomarkers.

Authors:  Lynnda J N van Tienhoven-Wind; Robin P F Dullaart
Journal:  Nutrients       Date:  2015-02-16       Impact factor: 5.717

6.  Elevated CETP Lipid Transfer Activity is Associated with the Risk of Venous Thromboembolism.

Authors:  Hiroshi Deguchi; Yajnavalka Banerjee; Darlene J Elias; John H Griffin
Journal:  J Atheroscler Thromb       Date:  2016-05-09       Impact factor: 4.928

7.  Increased leptin/adiponectin ratio relates to low-normal thyroid function in metabolic syndrome.

Authors:  Lynnda J N van Tienhoven-Wind; Robin P F Dullaart
Journal:  Lipids Health Dis       Date:  2017-01-11       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.